Search
Search
Invitrogen
{{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.promotions']}}
{{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.viewpromo']}}
{{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.promocode']}}: {{promo.promoCode}} {{promo.promoTitle}} {{promo.promoDescription}}. {{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.learnmore']}}
MA5-17530 targets pan T cells in FACS, IHC (F), and IP applications and shows reactivity with Rat samples.
The MA5-17530 immunogen is immunogen:PVG-RT1c thoracic duct lymphocytes and spleen cells.
Pan T cells, encompassing all T lymphocyte subsets, are integral to the adaptive immune system, originating from hematopoietic stem cells in the bone marrow and maturing in the thymus. These cells include helper T cells (CD4+), cytotoxic T cells (CD8+), regulatory T cells, and memory T cells, each playing distinct roles in immune defense. Pan T cells are characterized by the expression of the T-cell receptor (TCR) complex, which enables antigen recognition and response. The diversity within pan T cells allows for a broad range of functions, from direct cytotoxic effects on infected or malignant cells to regulatory roles in maintaining immune tolerance and memory responses for long-term immunity. These cells also interact with other immune components, enhancing or modulating responses to pathogens and tumors. Pan T cells are pivotal in cancer immunotherapy, where targeting specific T cell subsets can enhance anti-tumor immunity and overcome resistance mechanisms.
仅用于科研。不用于诊断过程。未经明确授权不得转售。